ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, the application of RUX in MF cannot be compared to the use of BCR-ABL-specific tyrosine kinase inhibitors (TKIs), such as imatinib, in patients transplanted for CML or Ph+ acute lymphoblastic leukemia (ALL) [128,129].